Emerging Issues and Trends In Clostridium Difficile Colitis

Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)

Clostridium difficile-associated diarrhea (CDAD) is a major cause of nosocomial and antibiotic-associated diarrhea, and it is the commonest recognized cause of pseudomembranous colitis. Despite the recognition of this pathogen since 1978 as the major cause of antibiotic-associated diarrhea, availability of treatment, and recognized infection control measures, CDAD has remained a persistent problem in most hospitals. Moreover, since 2002 renewed interest in this infection has been stimulated by epidemic outbreaks in hospitals in Canada, United States, United Kingdom, and the Netherlands secondary to a hypervirulent strain of C. difficile, associated with high recurrence and increased severity.

Although, a large body of literature exists on the pathogenesis, epidemiology, diagnostic methods, and management of CDAD, we still have no effective prevention and no optimal therapy for recurrences. The disease, is mostly a nuisance to healthy, young subjects, complicating antibiotic therapy, but can be a fatal disease in the elderly and high-risk population. It should be noted that despite our inability to conquer and prevent CDAD, there has been no new treatment on the market for this condition in the past 25 years.


Pseudomembranous Colitis Toxic Megacolon Oral Vancomycin Binary Toxin Leukemoid Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lyerly, D.M., Krivan, H.C., Wilkins, T.D., (1988) Clostridium difficile: its disease and toxins. Clin. Microbiol. Rev. 1:1–18.PubMedGoogle Scholar
  2. 2.
    Baverud, V., Gustafsson, A., Franklin, A., Aspan, A., Gunnarsson, A., (2003) Clostridium difficile: prevalence in horses and environment, and antimicrobial susceptibility. Equire Vet. J. 35:465–471.Google Scholar
  3. 3.
    Lyerly, D.M., Allen, S.D., (1997) The clostridia, in: Emmerson, A.M., Hawkey, P., Gille-spie, S. (ed)., Principles and Practice of Clinical Bacteriology. Wiley, New York; pp. 559– 623.Google Scholar
  4. 4.
    Ozaki, E., Kato, H., Kita, H., Karasawa, T., Maegawa, T., Koins, Y., Matsumoto, K., Takada, T., Nomoto, K., Tanaka, R., Nakamura, S., (2004) Clostridium difficilecolonization in healthy adults: transient colonization and correlation with enterococcal colonization. J. Med. Microbiol. 53:167–172.PubMedGoogle Scholar
  5. 5.
    Kato, H., Kita, H., Karasawa, T., Maegawa, T., Koino, Y., Takakuwa, H., Saikai, T., Kobayashi, K., Yamagishi, T., Nakamura, S., (2001) Colonization and transmission of Clostridium difficilein healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. J. Med. Microbiol. 50:720–727.PubMedGoogle Scholar
  6. 6.
    Savariau-Lacomme, M.P., Lebarbier, C., Karjalainen, T., Collignon, A., Janoir, C., (2003) Transcription and analysis of polymorphism in a cluster of genes encoding surface-associated proteins of Clostridium difficile. J. Bacteriol. 185:4461–4470.PubMedGoogle Scholar
  7. 7.
    Lemee, L., Bourgeois, I., Ruffin, E., Collingnon, A., Lemeland, J.F., Pons, J.L., (2005) Multilocus sequence analysis and comparative evolution of virulence-associated genes and housekeeping genes of Clostridium difficile. Microbiology 151:3171–3180.PubMedGoogle Scholar
  8. 8.
    Cohen, S.H., Tang, Y.J., Silva, J.R. J., (2000) Analysis of the pathogenicity locus in Clostridium difficilestrains. J. Infect. Dis. 181:659–663.PubMedGoogle Scholar
  9. 9.
    Barbut, F., Decre, D., Lalande, V., Burghoffer, B., Noussair, L., Gigandon, A., (2005) Clinical features of Clostridium difficile-associated diarrhea due to binary toxin (actin-specific ADP-ribosyltransferase) – producing strains. J. Med. Microbiol. 54:181–185.PubMedGoogle Scholar
  10. 10.
    Sehaihia, M., Wren, B.W., Mullang, P., Fairweather, N.F., Minton, N., Thomson, N.R., Roberts, A.P., Cerdeno-Tarraga, A.M., Wang, H., Holden, M.T., Wright, A., Churcher, C., Quail, M.A., Baker, S., Bason, N., Brooks, K., Chillingworth, T., Cronin, A., Davis, P., Dowd, L., Fraser, A., Feltwell, T., Hance, Z., Holroyd, S., Jagels, K., Moule, S., Mungall, K., Price, C., Rabbinowitsch, E., Sharp, S., Simmonds, M., Stevens, K., Unwin, L., Whithead, S., Dupuy, B., Dougan, G., Barrell, B., Parkhill, J., (2006) The multidrug-resistant human pathogen Clostridium difficilehas highly mobile, mosaic genome. Nature Genetics; 38:779–786.Google Scholar
  11. 11.
    Clabots, C.R., Johnson, S., Bettin, K.M., Mathie, P.A., Mulligan, M.E., Schaberg, L.R., Peterson, L.R., Gerding, D.N., (1993) Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficileand correlation with other typing system. J. Clin. Microbiol. 31:1870–1875.PubMedGoogle Scholar
  12. 12.
    Ward, P.B., Young, G.P., (1997) Dynamics of Clostridium difficileinfection. Control using diet. Advances Exp. Med. Biol. 412:63–75.Google Scholar
  13. 13.
    Tasteyre, A., Karjalainen, T., Avesani, V., Delmee, M., Collignon, A., Bourlioux, P., Barc, M.C., (2001) Molecular characterization of flid gene encoding flagellar cap and it's expression among Clostridium difficileisolates from different serogroups. J. Clin. Microbiol. 39:1178–1783.PubMedGoogle Scholar
  14. 14.
    Hennequin, C., Porcheray, F., Waligora-Dupriet, A., Collignon, A., Barc, M., Bourlioux, P., KarjaLainen, T., (2001) GroEl (Hsp60) of Clostridium difficileis involved in cell adherence. Microbiology 147:87–96.PubMedGoogle Scholar
  15. 15.
    Naaber, P., Lehto, E., Salminen, S., Mikelsaar, M., (1996) Inhibition of adhesion of Clostridium difficileto Caco-2cells. FEMS. Immunol. Med. Microbiol. 14:205–209.PubMedGoogle Scholar
  16. 16.
    Spigaglia, P., Mastrantonio, P., (2002) Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (tcdc) among Clostridi-um difficileclinical isolates. J. Clin. Microbiol. 40:3470–3475.PubMedGoogle Scholar
  17. 17.
    Rupnik, M., Avesani, V., Janc, M., von ichel-Streiber, C., Delmée, M., (1998) A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficileisolates. J. Clin. Microbiol. 36:2240–2247.PubMedGoogle Scholar
  18. 18.
    Sambol, S.P., Merrigan, M.M., Lyerly, D., Gerding, D.N., Johnson, S., (2000) Toxin gene analysis of a variant strain of Clostridium difficilethat causes human clinical disease. Infect. Immun. 68:5480–5887.PubMedGoogle Scholar
  19. 19.
    Alfa, M.J., Kabani, A., Lyerly, D., Moncrief, S., Neville, L.M., Al-Borrak, A., Harding, G. K., Dyck, B., Olekson, K., Embil, J.M., (2000) Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficileresponsible for a noscomial outbreak of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38:2706–2714.PubMedGoogle Scholar
  20. 20.
    Johson, S., Kent, S.A., O'Leary, K.J., Merrigan, M.M., Sambul, S.P., Peterson, L.R., Gerd-ing, D., (2001) Fatal pseudomembranous colitis associated with a variant Clostridium difficilenot detected by toxin A immuno assay. Ann. Intern. Med. 135:434–438.Google Scholar
  21. 21.
    Kuijper, E.J., de Weerdt, J., Kato, H., Kato, N., van Dam, A.P., van der Vorm, E.R., Weel, J., van Rheenen, C., Dankert, J., (2001) Nosocomial outbreak of Clostridium difficile-associated diarrhea due to a clindamycin-resistant enterotoxin A-negative strain. Eur. J. Clin. Microbiol. Infect. Dis. 20:528–534.PubMedGoogle Scholar
  22. 22.
    Komatsu, M., Kato, H., Aikara, M., Aihara, M., Shimakawa, K., Iwasaki, M., Nagasaka, Y., Fukuda, S., Matsuo, S., Arakawa, Y., Watanabe, M., Iwatani, Y., (2003) High frequency of antibiotic-associated diarrhea due to toxin A negative, toxin B-positive Clostridium difficilein a hospital in Japan and risk factors for infection. Eur. J. Clin. Microbiol. Infect. Dis. 22:525–529.PubMedGoogle Scholar
  23. 23.
    Barbut, F., Lalande, V., Burghoffer, B., Thien, H.V., Grimprel, E., Petit, J.C., (2002) Prevalence and genetic characterization of toxin A variant strains of Clostridium difficileamong adults and children with diarrhea in France. J. Clin. Microbiol. 40:2079–2083.PubMedGoogle Scholar
  24. 24.
    Pituch, H., van den Braak, N., Van Leeuwen, W., Van Belkum, A., Martirosian, G., Obuch-Woszczatynski, P., Luczak, M., Meisel-Mlkolajczyk, F., (2001) Clonal dissemination of a toxin-A-negative/toxin-B-positive Clostridium difficilestrain from patients with antibiotic-associated diarrhea in Poland. Clin. Microbiol. Infect. 7:442–446.PubMedGoogle Scholar
  25. 25.
    Moncreif, J., Zheng, L., Neville, L.M., Lyerly, D.M., (2000) Genetic characterzarion of toxin A-negative, toxin B-positive Clostridium difficileisolates by PCR. J. Clin. Microbiol. 38:3072–3075.Google Scholar
  26. 26.
    Cohen, S.H., Tang, Y.J., Hansen, B., Silva, J. Jr., (1998) Isolation of a toxin B-deficient mutant strain of Clostridium difficilein case of recurrent C. difficile-associated diarrhea. Clin. Infect. Dis. 26:410–412.PubMedGoogle Scholar
  27. 27.
    Moncrief, J.S., Lyerly., S.D., Wilkins, T.D., (1997) Moleculer biology of the Clostridium difficiletoxins, In: Rood, J.I., McClane, B.A., Songer, J.G., Titball, R.W. (eds) The Clostridia: Molecular Biology and Pathogenesis. Academic Press, New York, pp. 369–392.Google Scholar
  28. 28.
    Gerard, N.P., Pothoulakis, C., (1998) Neurokinin-1(NK-D) receptor is required in Clostridi-um difficile-induced enteritis. J. Clin. Invest. 101:1547–1550.PubMedGoogle Scholar
  29. 29.
    Na, X., Moyer, M.P., Pothoulakis, C., La-Mont, J.T., (2008) gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficiletoxin A. Infect. Immun 76: 2862– 2871.PubMedGoogle Scholar
  30. 30.
    Rocha, M.F., Sidrim, J.J., Lima, A.A., (1999) Clostridium difficileas an inducer of inflammatory diarrhea. Revista SOC. Brasil. Med. Trop. 32:47–52.Google Scholar
  31. 31.
    Keel, M.K., Songer, J.G., (2006) The comparative pathology of Clostridium difficile-associated disease. Vet. Path. 43:225–240.Google Scholar
  32. 32.
    Alcantara, C., Stenson, W.F., Steiner, T.S., Guerrant, R.L., (2001) Role of inducible cyclooxygenase and prostaglandins in Clostridium difficiletoxin A-induced secretion and inflammation in an animal model. J. Infect. Dis. 184:648–652.PubMedGoogle Scholar
  33. 33.
    Ishida, Y., Maegawa, T., Kono, T., Kimura, A., Iwakura, Y., Nakamura, S., Mukaida, N., (2004) Essential involvement of IFN-gamma in Clostridium difficiletoxin A-induced enteritis. J. Immunol. 172:3018–3025.PubMedGoogle Scholar
  34. 34.
    Warny, M., Keates, A.C., Keates, S., Castagliuolo, I., Zacks, J.K., Qamor, A., Pothoulakis, C., Lamont, J.T., Kelly, C.P., (2000) p 38 MAP kinase activation by Clostridiumtoxin A mediates monocyte necrosis, 1 L-8 production, and enteritis. J. Clin. Invest. 105:1147–1156.PubMedGoogle Scholar
  35. 35.
    Solomon, K., Webb, J., Ali, N., Robins, R.A., Mahida, Y.R., (2005) Monocytes are highly sensitive to Clostridium difficiletoxin A-induced apoptotic and nonapototic cell death. Infect. Immun. 73:1625–1634.PubMedGoogle Scholar
  36. 36.
    Stubbs, S., Rupnik, M., Gibert, M., Brazier, J., Duerden, B., Popoff, M., (2000) Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol. Lett. 186:307–312.PubMedGoogle Scholar
  37. 37.
    Barth, H., Aktories, K., Popoff, M.R., Stiles, B.G., (2004) Binary bacterial toxins: biochemistry, biology, and applications of common Clostridiumand Bacillusproteins. Microbiol. Mol. Biol. Rev. 68:373–402.PubMedGoogle Scholar
  38. 38.
    Justus, P.G., Martin, J.L., Goldberg, D.A., Taylor, N.S., Bartlett, J.G., Alexander, R.W., Mathians, J.R., (1982) Myoelectric effects of Clostridium difficile: motility-altering factors distinct from cytotoxin and enterotoxin in rabbits. Gastro-enterology; 83:836–843.Google Scholar
  39. 39.
    Geric, B., Rupnik, M., Gerding, P.N., Grabnar, M., Johnson, S., (2004) Distribution of Clostridium difficilevariant toxinotypes with binary toxin genes among clinical isolates in a American hospital. J. Med. Microbiol. 53:887–894.PubMedGoogle Scholar
  40. 40.
    Goncalves, C., Decré, D., Barbut, F., Burghoffer, B., Petit, J.C., (2004) Prevalence and characterization of a binary toxin (action-specific ADP-ribosyltransferase) from Clostridium difficile. J. Clin. Microbiol. 42:1933–1939.PubMedGoogle Scholar
  41. 41.
    Terhes, G., Urban, E., Soki, J., Hamid, K.A., Nagy, E., (2004) Community-acquired Clostridium difficilediarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J. Clin. Microbiol. 42:4316–4318.PubMedGoogle Scholar
  42. 42.
    Geric, B., Johnson, S., Gerding, D.N., Grabnar, M., Rupnik, M., (2003) Frequency of binary toxin genes among Clostridium difficilestrains that do not produce large clostridial toxins. J. Clin. Microbiol. 41:5227–5232.PubMedGoogle Scholar
  43. 43.
    McEllistrem, M.C., Carmen, R.J., Gerding, D.N., Genheimer, C.W., Zheng, L., (2005) A hospital outbreak of Clostridium difficiledisease associated with isolates carrying binary toxin genes. Clin. Infect. Dis. 40:265–272.PubMedGoogle Scholar
  44. 44.
    Barbut, F., Decre, D., Lalonde, V., Burghoffer, B., Noussair, L., Gigandon, A., Espinasse, F., Raskine, L., Robert, J., Mangeol, A., Branger, C., Petit, J.C., (2005) Clinical features of Clostridium difficile-associated diarrhea due to binary toxin (actin-specific ADP-ribosyl-transferase)-producing strains. J. Med. Microbiol. 54:181–185.PubMedGoogle Scholar
  45. 45.
    McDonald, L.L., Gielgore, G.E., Thompson, A., Owens Jr., R.C., Kazakova, S.V., Sambol, S.P., Johson, S., Gerding, D.N., (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433–2441.PubMedGoogle Scholar
  46. 46.
    Geric, B., Carmen, R.J., Rupnik, M., Genheimer, C.W., Sambol, S.P., Lyerly, D.M., Gerd-ing, D.N., Johnson, S., (2006) Binary toxin-producing, large clostridial toxin-negative Clostridium difficilestrains are enterotoxic but do not cause disease in hamsters. J. Infect. Dis. 193:1143–1150.PubMedGoogle Scholar
  47. 47.
    Loo, V.G., Poirier, L., Miller, M.A., Oughton, M., Libman, M.D., Michaud, S., Borgault, A. M., Nguyen, T., Frenette, C., Kelly, M., Vibien, A., Brassard, P., Fenn, S., Dewar, K., Hudson, T.J., Horn, R., Rene, P., Monczak, Y., Dascal, A., (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2503–2505.Google Scholar
  48. 48.
    Kuijer, E.J., van den Berg, R.J., Debast, S., Visser, C.E., Veenendaal, D., Troelstra, A., van der Kooi, T., van den Hof, S., Notermans, D.W., (2006) Clostridium difficileribotype 027, toxinotype III, the Netherlands. Emerg. Infect. Dis. 12:827–830.Google Scholar
  49. 49.
    Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., McDonald, L.C., (2005) Toxin production by an emerging strain of Clostridium difficileassociated with severe disease in North America and Europe. Lancet 366:1079–1084.PubMedGoogle Scholar
  50. 50.
    Songer, J.G., (2004) The emergence of Clostridium difficileas a pathogen of food animals. Animal Health Res. Rev. 5:321–326.Google Scholar
  51. 51.
    Baverud, V., Franklin, A., Gunnarsson, A., Gustafsson. A., Hellander-Edman, A., (1998) Clostridium difficileassociated with acute colitis in mares when their foals are treated with erythromycin and rifampicin for Rhodococcus equipneumonia. Equine Vet. J. 30:482–488.PubMedGoogle Scholar
  52. 52.
    Bojesen, A.M., Olsen, K.E., Bertelsen, M.F., (2006) Fatal enterocolitis in Asian elephants (Elephas maximus) caused by Clostridium difficile. Vet. Microbiol. 116:329–335.PubMedGoogle Scholar
  53. 53.
    Chouicha, N., Marks, L.S., (2006) Evaluation of five enzyme immunoassays compared with the cytotoxicity assay for diagnosis of Clostridium difficileassociated diarrhea in dogs. J. Vet. Diag. Invest. 18:182–188.Google Scholar
  54. 54.
    Wanahita, A., Goldsmith, E.A., Musher, D.M., (2002) Conditions associated with leucocy-tosis in a territory care hospital with particular attention to the role of infection caused by Clostridium difficile. Clin. Infect. Dis. 34:1585–1592.PubMedGoogle Scholar
  55. 55.
    Marinella, M.A., Burdette, S.A., Bedimo, R., Markert, R.J., (2004) Leukemoid reactions complicating colitis due to Clostridium difficileSouth. Med. J. 97:959–963.PubMedGoogle Scholar
  56. 56.
    Zachariadis, G., Connon, J.J., Fong, I.W., (2002) Fulminant Clostridium difficilecolitis without diarrhea: Lack of emphasis in diagnostic guidelines. Am. J. Gastroent. 97:2929– 2930.Google Scholar
  57. 57.
    Bartlet, J.G., (2006) Narrative review: The new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145:758–764.Google Scholar
  58. 58.
    Longo, W.E., Mazuski, J.E., Virgo, K.S., Lee, P., Bahadursingh, A.N., Johnson, F.E., (2004) Outcome after colectomy for Clostridium difficilecolitis. Dis. Colon Rectum 47:1620–1626.PubMedGoogle Scholar
  59. 59.
    Asha, N.J., Tompkins, D., Wilcox, M.H., (2006) Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococus aureus. J. Clin. Microbiol. 44:2785– 2791.PubMedGoogle Scholar
  60. 60.
    Sohn, S., Climo, M., Diekema, D., Fraser, V., Herwaldt, L., Marino, S., Noskin, G., Perl, T., Song, X., Tokars, J., Warren, D., Wong, E., Yokoe, D.S., Zembower, T., Sepkowitz, K.A., (2005) Varying rates of Clostridium difficile-associated diarrhea at prevention epicenter hospitals. Infect. Cont. Hosp. Epid. 26:676–679.Google Scholar
  61. 61.
    Noren, T., Akerlund, T., Back, E., Sjoberg, L., Persson, I., Alriksson, I., Burman, L.G., (2004) Molecular epidemiology of hospital-associated and community-acquired Clostridi-um difficileinfection in a Swedish county. J. Clin. Microbiol. 42:3635–3643.PubMedGoogle Scholar
  62. 62.
    Maraki, S., Georgiladakis, A., Tselentis, Y., Samonis, G., (2003) A 5 year study of the bacterial pathogens associated with acute diarrhea on the island of Crete, Greece, and their resistance to antibiotics. Eur. J. Epid. 18:85–90.Google Scholar
  63. 63.
    Karlstrőm, O., FrykLund, B., Tullus, K., Burman, L.G., and the Swedish C. difficileStudy Group, (1998) A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. Clin. Infect. Dis. 26:141–145.PubMedGoogle Scholar
  64. 64.
    Gottlieb, A.L., Gayles, M.K., Grahn, K.F., Chavez-Perez, V.M., Salas Apolinario, I., Gil-man, R.H., (1998) Diarrhea and Clostridium difficileinfection in Latin American patients with AIDS. Working Group on AIDS in Peru. Clin. Infect. Dis. 27:487–493.PubMedGoogle Scholar
  65. 65.
    Sanchez, T.H., Brooks, J.T., Sullivan, P.S., Juhasz, M., Mintz, E., Dwarkin, M.S., Jones, J.L., and the adult/adolescent spectrum of HIV Disease Study Group, (2005) Bacterial diarrhea in persons with HIV infection, United States, 1999–2002. Clin. Infect. Dis. 41:1621–1627.PubMedGoogle Scholar
  66. 66.
    Centers for Disease Control and Prevention, (2005) Severe Clostridium difficile-associated disease in populations at low risk–four states. MMWR Morb. Mortal Wkly Rep. 54:1201–1205.Google Scholar
  67. 67.
    Klein, E.J., Boster, D.R., Stapp, J.R., Wells, J.G., Qin, X., Clausen, C.R., SwerdLow, D.L., Braden, C.R., Tarr, P.I., (2006) Diarrhea etiology in children's hospital emergency department: a prospective cohort study: Clin. Infect. Dis. 43:807–813.Google Scholar
  68. 68.
    Vesikori, T., Jsolauri, E., Maki, M., Gronroos, P., (1984) Clostridium difficilein young children: association with antibiotic usage. Acta Paediatr. Scand. 73:86–91.Google Scholar
  69. 69.
    Pepin, J., Valiquette, L., Alary, M.E., Villemure, P., Pelletier, A., Forget, K., Pépin, K., Chouinard, D., (2001) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472.Google Scholar
  70. 70.
    Pepin, J., Valiquette, L., Cosselte, B., (2005) Mortality attributable to nosocominal Clos-tridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037–1042.PubMedGoogle Scholar
  71. 71.
    Kyne, L., Hamel, M.B., Polavaram, R., Kelly, C.P., (2002) Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34:346– 353.PubMedGoogle Scholar
  72. 72.
    Erikson, S., Aronsson, B., (1989) Medical implications of nosocomial infection with Clostridium difficile. Scand. J. Infect. Dis. 21:733–734.Google Scholar
  73. 73.
    McDonald, L.C., (2005) Clostridium difficile: responding to a new threat from an old enemy. Infect. Control. Hosp. Epidemiol. 26:672–675 (editorial).PubMedGoogle Scholar
  74. 74.
    Dallal, R.M., Harbrecht, B.C., Boujoukas, A.J., Sirio, C.A., Farkas, L.M., Lee, K.K., Simmons, R.L., (2002) Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann. Surg. 235:363–372.PubMedGoogle Scholar
  75. 75.
    Muto, C.A., Pokrywka, M., Shutt, K., Mendelsohn, A.B., Nouri, K., Posey, K., (2005) A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26:273–280.PubMedGoogle Scholar
  76. 76.
    Owens, R.C., (2006) Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the society of Infectious Disease Pharmacists. Pharmacotherapy 26:299–311.PubMedGoogle Scholar
  77. 77.
    Beaugerie, L., Metz, M., Barbut, F., Bellaiche, G., Bouhnik, Y., Raskine, L., Nicholas, J.-C., Chatelet, F.-P., Lehn, N., Petit, J.C., and the Infectious Colitis Study Group (2003) Klebsi-ella oxytocaas an agent of antibiotic-associated hemorrhagic colitis. Clin. Gastroenteriol. Hepatol. 1:370–376.Google Scholar
  78. 78.
    Toffler, R.B., Pingound, E.G., Burrell, M.I., (1978) Acute colitis related to penicillin derivatives. Lancet 2:707–709.PubMedGoogle Scholar
  79. 79.
    Koga, H., Aoyagi, K., Yoshimura, R., Kimura, Y., Lida, M., Fujishima, M., (1999) Can quinolones cause hemorrhagic colitis of late onset? Report of three cases. Dis. Colon Rectum 42:1502–1504.PubMedGoogle Scholar
  80. 80.
    Bellaiche, G., Le Pennec, M.P., Choudat, L., Ley, G., Shama, J.L., (1997) Value of rectosigmoidoscopy with bactericological culture of colonic biopsies in the diagnosis of post-antibiotic hemorrhagic colitis related to Klebsiella oxytoca. Gastroenterol. Clin. Biol. 21:764–767.PubMedGoogle Scholar
  81. 81.
    Hőgenauer, C., Langner, C., Beubler, E., Lippe, I.T., Schicho, R., Gorkiewicz, G., Krause, R., Grestgrasser, N., Krejs, G.J., Hinterleitner, T.A., (2006) Klebsiella oxytocaas a causative organism of antibiotic-associated hemorrhagic colitis. N. Engl. J. Med. 355:2418–2426.PubMedGoogle Scholar
  82. 82.
    Bergogne-Berezin, E., (2000) Treatment and prevention of antibiotic associated diarrhea. Internat. J. Antimicrob. Agents: 16:521–526.Google Scholar
  83. 83.
    Johnson, S., Samore, M.H., Farrow, K.A., Killgore, G.E., Tenover, F.C., Lyras, D., Rood, J. I., DeGirolami, P., Baltch, A.L., Rafferty, M.E., Pear, S.M., Gerding, D.N., (1999) Epidemics of diarrhea caused by clindamycin-resistant strain of Clostridium difficilein four hospitals. N. Engl. J. Med. 341:1645–1651.PubMedGoogle Scholar
  84. 84.
    Noren, T., Tang-Feldman, Y.J., Cohen, S.H., Silva, J. Jr., Olcen, P., (2002) Clindamycin resistant strains of Clostridium difficileisolated from cases of C. difficileassociated diarrhea (CDAD) in hospital in Sweden. Diag. Microbiol. Infect. Dis. 42:149–151.Google Scholar
  85. 85.
    Climo, M.W., Israel, D.S., Wong, E.S., Williams, D., Coudron, P., Markowitz, S.M., (1998) Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann. Interm. Med. 128:989–995.Google Scholar
  86. 86.
    Wilcox, M.H., Freeman, J., Fawley, W., Mackinlay, S., Brown, A., Donaldson, K., Corrado, O., (2004) Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficilediarrhea. J. Antimicrob. Chemother 54:168–172.PubMedGoogle Scholar
  87. 87.
    Starr, J.M., Impallomeni, M., (1997) Risk of diarrhea, Clostridium difficileand cefotaxime in the elderly. Biomed. Pharmacother. 51:63–67.PubMedGoogle Scholar
  88. 88.
    Settle, C.D., Wilcox, M.H., Fawley, W.N., Corrado, O.J., Hawkey, P.M., (1998) Prospective study of the risk of Clostridiumdiarrhea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment. Pharmacol. Ther. 12:1217–1223.PubMedGoogle Scholar
  89. 89.
    Yip, C., Loeb, M., Salama, S., Moss, L., Olde, J., (2001) Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect. Control Hosp. Epidemiol. 22:572–575.PubMedGoogle Scholar
  90. 90.
    Ackermann, G., Tang-Feldman, Y.J., Schaumann, R., Henderson, J.P., Rodloff, A.C., Silva, J., Cohen, S.H., (2003) Antecedent use of fluoroquinolones is associated with resitance to moxifloxacin in Clostridium difficile. Clin. Microbiol. Infect. 9:526–530.PubMedGoogle Scholar
  91. 91.
    Gaynes, R., Rimland, D., Killum, E., Lowery, H.K., Johson, T.M., 2nd, Killmore, G., Tenover, F.C., (2004) Outbreak of Clostridium difficileinfection in a long-term care facility: association with gatifoxacin use. Clin. Infect. Dis. 38:640–645.PubMedGoogle Scholar
  92. 92.
    Pepin, J., Saheb, N., Coulombe, M.A., Alory, M.E., Corriveau, M.P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., Ngugen, M., Jacob, C.E., Lanthier, L., (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1250–1260.Google Scholar
  93. 93.
    McCusker, M.E., Harris, A.D., Perencevich, E., Roghmann, M.C., (2003) Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg. Infect. Dis. 9:730–733.PubMedGoogle Scholar
  94. 94.
    Gerding, D.N., (2005) Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin. Infect. Dis. 38:646–648 (editorial).Google Scholar
  95. 95.
    Pituch, H., Brazier, J.S., Obuch-Woszczatynski, P., Waltanska, D., Meissel-Mikolajczyk, F., Luczak, M., (2006) Prevalence and association of PCR ribotypes of Clostridium difficileisolated from symptomatic patients from Warsaw with macrolide-lincoamide-streptogramin B (MLSB) type resistance. J. Med. Microbiol. 55:207–213.PubMedGoogle Scholar
  96. 96.
    Surawicz, C.W., (2005) Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials. Chemotheropy 51(Suppl I):81–89.Google Scholar
  97. 97.
    Jennings, L.J., Hanumandass, M., (1998) Silver sulfadiazine induced Clostridium difficiletoxic megacolon in a burn patient: case report. Burns 24:676–679.PubMedGoogle Scholar
  98. 98.
    Akutagawa, H., Takada, E., Egashira, Y., Adachi, G., Kurisu, Y., Edagawa, G., Hirata, I., Katsu, K., Shibayama, Y., (2004) Four cases of pseudomembranous colitis due to antitu-berculous agents. Jap. J. Gastroenterol. 101:890–894.Google Scholar
  99. 99.
    Kerst, J.M., Van der Lelie, J., Kuijper, E.J., (2001) Diarrhea due to Clostridium difficiletoxin in hematooncological patients. Ned. Tijdschr. GeneesKd. 145:1137–1140.PubMedGoogle Scholar
  100. 100.
    Wong, A.S., Lam, C.S., Tambyah, P.A., (2001) Fatal chemotherapy associated Clostridium difficileinfection – a case report. Singapore Med. J. 42:214–216.PubMedGoogle Scholar
  101. 101.
    Center for Disease Control & Prevention, (2005) Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. Morb. Montal Wkly Rep. CDC 54:1201–1205.Google Scholar
  102. 102.
    Beaulieu, M., Thirion, D.J.G., Williamson, D., Pichette, G., (2006) Clostridium difficile-associated outbreaks: the name of the game is isolation and cleaning. Clin. Infect. Dis. 42:725–52(letter).PubMedGoogle Scholar
  103. 103.
    Weiss, K., (2006) Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile–associated diarrhea outbreaks in Quebec. Clin. Infect. Dis. 42:725–727 (letter).PubMedGoogle Scholar
  104. 104.
    Svenungsson, B.O., Burman, L.G., Jalakas-Pornull, K., Lagergren, A., Struwe, J., Akerlund, T., (2003) Epidemiology and molecular characterization of Clostridium difficilestrains from patients with diarrhea: low disease incidence and evidence of limited cross-infection is a Swedish teaching hospital. J. Clin. Microbiol. 41:4031–4037.PubMedGoogle Scholar
  105. 105.
    Palmore, T.N., Sohn, S., Malak, S.F., Eagan, J., Sepkowitz, K.A., (2005) Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect. Control Hosp. Epidemiol. 26:680–684.PubMedGoogle Scholar
  106. 106.
    Barbut, F., Corthier, G., Charpak, Y., Cerf, M., Monteil, H., Fosse, T., Trevoux, A., Barbeyrac, B., Boussougnant, Y., Tigaud, S., Tytgat, F., Sedallian, A., Duborgel, S., Col-lignon, A., Le Guern, M.E., Bernasconi, P., Petit, J.C., (1996) Prevalence and pathogenicity of Clostridium difficilein hospitalized patients. A French multicentre study. Arch. Intern. Med. 156:1449–1454.PubMedGoogle Scholar
  107. 107.
    Schwaber, M.J., Simhon, A., Block, C., Roval, V., Ferderber, N., Shapiro, M, (2000) Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 19:9–15.Google Scholar
  108. 108.
    Ho, M., Yang, D., Wyle, F.A., Mulligan, M.E., (1996) Increased incidence of Clostridium difficile-associated diarrhea following decreased restriction of antibiotic use. Clin. Infect. Dis. 23(Suppl I): S102–S106.PubMedGoogle Scholar
  109. 109.
    Samore, M.H., Venkataraman, L., De Girolami, P.C., Arbeit, R.D., Karchmer, A.W., (1996) Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clos-tridium difficilediarrhea. Am. J. Med. 100:32–40.PubMedGoogle Scholar
  110. 110.
    Mody, L.R., Smith, S.M., Dever, L.L., (2001) Clostridium difficile-associated diarrhea in a VA medical center: clustering of cases, associated with antibiotic usage, and impact on HIV-infected patients. Infect. Control Hosp. Epidemiol. 22:42–45.PubMedGoogle Scholar
  111. 111.
    Henoun Loukili, N., Martinot, M., Hansmann, Y., Christmann, D., (2004) Risk factors for nosocomial Clostridium difficilediarrhea in an infectious and tropical diseases department. Med. Malad. Infect. 34:57–61.Google Scholar
  112. 112.
    Bignardi, G.E., (1998) Risk factors for Clostridium difficileinfection. J. Hosp. Infect. 40:1–15.PubMedGoogle Scholar
  113. 113.
    Cunningham, R., Dale, B., Undy, B., Gaunt, N., (2003) Proton pump inhibitors as a risk factor for Clostridium difficilediarrhea. J. Hosp. Infect. 54:243–245.PubMedGoogle Scholar
  114. 114.
    Dial, S., Alrasadi, K., Manoukian, C., Huang, A., Menzies, D., (2004) Risk of Clostridium difficileamong hospital inpatients prescribed proton pump-inhibitors: cohort and case-control studies. CMAJ 171:33–38.PubMedGoogle Scholar
  115. 115.
    Shah, S., Lewis, A., Leapold, D., Dunstan, F., Woodhouse, K., (2000) Gastric acid suppression does not promote clostridial diarrhea in the elderly. Quat. J. Med. 93:175–181.Google Scholar
  116. 116.
    Al-Tureihi, F.I., Hassoun, A.,Wolf-Klein, G., Isenberg, H., (2005) Albumin, length of stay, and proton pump inhibitors: Key factors in Clostridium difficileassociated disease in nursing home patients. J. Am. Med. Dir. Assoc. 6:105–108.PubMedGoogle Scholar
  117. 117.
    Dial, S., DeLaney, J.A.C., Barkun, A.N., Suissa, S., (2005) Use of gastric-acid suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294:2989–2995.PubMedGoogle Scholar
  118. 118.
    Lowe, D.O., Mamdani, M.M., Kopp, A., Low, D.E., JuurLink, D.N., (2006) Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: A population based study. Clin. Infect. Dis. 43:1272–1276.PubMedGoogle Scholar
  119. 119.
    vanStaa, T.-P., Leufkens, H.G.M., (2006) Gastric acid-suppression agents and risk of Clostridium difficile-associated disease. JAMA 295:2599 (letter).Google Scholar
  120. 120.
    Dial, S., Delaney, J.A.C., Schneider, V., Suissa, S., (2006) Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175:745–748.PubMedGoogle Scholar
  121. 121.
    Cunningham, R., (2006) Proton pump inhibitors and the risk of Clostridium difficile-associated disease: further evidence from the community. CMAJ 175:757–758.PubMedGoogle Scholar
  122. 122.
    Fedorker, D.P., Engler, H.D., Ó Shaughnessy, E.M., Williams, E.C., Reichelderfer, C.J., Smith, W.I. Jr., (1999) Evaluation of two rapid assays for detection of Clostridium difficiletoxin A in stool specimens. J. Clin. Microbiol. 39:3044–3047.Google Scholar
  123. 123.
    Ticehurst, J.R., Aird, D.Z., Dam, L.M., Borek, A.P., Hargrove, J.T., Carroll, K.C., (2006) Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J. Clin. Microbiol. 44:1145–1149.PubMedGoogle Scholar
  124. 124.
    Vanpouke, H., DeBaere, T., Claeys, G., Vaneechoutte, M., Verschraegen, G., (2001) Evaluation of six commercial assays for the rapid detection of Clostridium difficiletoxin and/or antigen in stool specimens. Clin. Microbiol. Infect. 7:55–64.Google Scholar
  125. 125.
    Lemee, L., Dhalluin, A., Testelin, S., Mattrat, M.A., Maillard, K., Lemeland, J.F., Pons, J.-L., (2004) Multiplex PCR targeting tpi (Triose Phosphate Isomerase) tcdA (Toxin A) and tcdB (ToxinB) genes for toxigenic culture of Clostridium difficile. J. Clin. Microbiol. 42:5710– 5714.PubMedGoogle Scholar
  126. 126.
    Van den Berg, R.J., Bruijnesteijn van Coppenraet, L.S., Gerritsen, H.J., Endtz, H.P., van der Vorm, E.R., Kuijper, E.J., (2005) Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J. Clin. Microbiol. 43:5338–5340.PubMedGoogle Scholar
  127. 127.
    Guilbault, C., Labbe, A.C., Poirier, L., Busque, L., Beliveau, C., Laverdiere, M., (2002) Development and evaluation of a PCR method for detection of the Clostridium difficiletoxin B gene in stool specimens. J. Clin. Microbiol. 40:2288–2290.PubMedGoogle Scholar
  128. 128.
    van den Berg, R.J., Kuijper, E.J., van Coppenraet, L.E., Claas, E.C., (2006) Rapid diagnosis of toxigenic Clostridium difficilein faecal samples with internally controlled real-time PCR. Clin. Microbiol. Infect. 12:184–186.PubMedGoogle Scholar
  129. 129.
    Teasley, D.G., Gerding, D.N., Olson, M.M., Peterson, L.R., Gebhard, R.L., Schwartz, M.J., (1983) Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet; 2:1043–1046.PubMedGoogle Scholar
  130. 130.
    Wenisch, C., Parschalk, B., Hasenhiindl, M., Hirschl, A.M., Graninger, W., (1996) Comparison of vancomycin, teichoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 22:813–818.PubMedGoogle Scholar
  131. 131.
    Shin, J.W., Yong, D., Kim, M.S., Chang, K.H., Lee, K., Kim, J.M., Chong, Y., (2003) Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J. Infect. Chemother. 9:104–105.Google Scholar
  132. 132.
    PeLáez, T., AlcoLá, L., Alonso, R., Rodriguez-Créixems, M., Garcia-Lechuz, Bouza, E., (2002) Reassessment of Clostridium difficilesusceptibility to metronidazole and vancomy-cin, Antimicrob. Agents Chemother. 46:1647–1650.Google Scholar
  133. 133.
    Freeman, J., Stott, J., Baines, S.D., Fawley, W.N., Walcox, M.H., (2005) Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficileisolates in a large teaching hospital. J. Antimicrobial Chemother 156:988–989.Google Scholar
  134. 134.
    Barbut, F., Decre, D., Burghoffer, B., Lesage, D., Delisle, E., Lalande, V., Delmee, M., Avesani, V., Sano, N., Coudert, C., Petit, J.L., (1999) Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficileisolated in France in 1991 and 1997. Antimicrob. Agents Chemother. 43:2607–2611.PubMedGoogle Scholar
  135. 135.
    Wong, S.S., Woo, P.C., Luk, W.K., Yuen, K.Y., (1999) Susceptibility testing of Clostridium difficileagainst metronidazole, and vancomycin by disc diffusion and Etest. Diag. Microbial. Infect. Dis. 34:1–6.Google Scholar
  136. 136.
    Pépin, J., Alary, M.-E., Valiguette, Raiche, E., Ruel, J., Fulop, K., Godin, D., Bourassa, C., (2005) Increasing risk of relapse after treatment of Clostridium difficilecolitis in Quebec, Canada. Clin, Infect. Dis. 40:1591–1597.Google Scholar
  137. 137.
    Musher, D.M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., Hamill, R.J., (2005) Relatively poor outcome after treatment of Clostridium difficilecolitis with metroni-dazole. Clin. Infect. Dis. 40:1586–1590.PubMedGoogle Scholar
  138. 138.
    Wilcox, M.H., Howe, R., (1995) Diarrhea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J. Antimicrob. Chemother. 36:673–679.PubMedGoogle Scholar
  139. 139.
    Bolton, R.P., Culshaw, M.A., (1986) Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut; 27:1169–1172.PubMedGoogle Scholar
  140. 140.
    Bricker, E., Garg, R., Nelson, R., Loza, A., Novak, T., Hansen, J., (2005) Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. CD004610.Google Scholar
  141. 141.
    Keighley, M.R., Burdon, D.W., Arabi, Y., W.Lliams, J.A., Thompson, H., Young, D., Johnson, M., Bentley, S., George, R.H., Mogg, G.A., (1998) Randomized controlled trail of vancomycin for pseudomembranous colitis and post-operative diarrhea. Brit. Med. J. 2:1667–1669.Google Scholar
  142. 142.
    Zar, F.A., Bakkanagari, S.-R., Moorthi, K.M.L.S.T., Davis, M.B., (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302–307.PubMedGoogle Scholar
  143. 143.
    Kupers, E.J., Surawicz, C.M., (2008) Clostriduim difficileinfection. Lancet. 371: 1486–1488.Google Scholar
  144. 144.
    Bartlett, J.G., (2008) The case for vancomycin as the preferred drug for treatment of Clostridium difficileinfection. Clin. Infect. Dis. 46:1489–1492.PubMedGoogle Scholar
  145. 145.
    Pepin, J., (2008) Vancomycin for the treatment of Clostridium difficileinfection: for whom is this expensive bullet really magic? Clin. Infect. Dis. 46:1493–1498.Google Scholar
  146. 146.
    Johnson, S., Homann, S.R., Bettin, K.M., Quick, J.N., Clabots, C.R., Peterson, L.R., Gerd-ing, D.N., (1992) Treatment of asymptomatic Clostridium difficilecarriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann. Intern Med. 117:297–302.PubMedGoogle Scholar
  147. 147.
    Lagrotteria, D., Holmes, S., Smieja, M., Smaill, F., Lee, C., (2006) Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 43:547–552.PubMedGoogle Scholar
  148. 148.
    Kurtz, C.B., Cannon, E.P., Brezzani, A., Pitruzzello, M., Dinardo, C., Rinard, E., Acheson, D.W., Fitzpatrick, R., Kelly, P., Shackett, K., Papoulis, A.T., Goddard, P.J., Barker, R.A. Jr., Palace, G.P., Klinger, J.D., (2001) GTIGO-246, a toxin binding polymer for treatment of Clostridium difficilecolitis. Antimicrob. Agents Chemother. 45: 2340–2347.PubMedGoogle Scholar
  149. 149.
    Braunlin, W., Xu, Q, Hook, P., Fitzpatrick, R., Klinger, J.D., Burrier, R., Kurtz, C.B., (2004) Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J. 87:534–539.PubMedGoogle Scholar
  150. 150.
    Louie, T.J., Peppe, J., Watt, C.K., Johnson, D., Mohammed, R., Dow, G., Weiss, K., Simon, S., John, J.F. Jr., Garber, G., Chasen-Taber, S., Davidson, D.M., for the Tolevamer Study Investigator Group, (2006) Tolevamer, a noval nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderate severe Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 43:411–420.PubMedGoogle Scholar
  151. 151.
    White, C.A. Jr., (2004) Nitazoxanide: a new broad spectrum antiparasitic agent. Expert. Rev. Anti; Infect. Ther. 2:43–49.PubMedGoogle Scholar
  152. 152.
    Fox, L.M., Saravolatz, L.D., (2005) Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40:1173–1180.PubMedGoogle Scholar
  153. 153.
    Broekhuysen, J., Stockis, A., Lins, R.L., De Graeve, J., Rossignol, J.F., (2000) Nitazox-anide: pharmacokinetics and metabolism in man. Int. J. Clin. Phamacol. Ther. 38:387–394.Google Scholar
  154. 154.
    Dubreuil, L., Houcke, I., Mouton, Y., Rossignol, J.F., (1996) In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. 40:2266–2270.PubMedGoogle Scholar
  155. 155.
    Musher, D.M., Logan, N., Hamill, R.J., Dupont, H.L., Lentnek, A., Gupta, A., Rossignol, J.-F., (2006) Nitazoxanide for the treatment of Clostridium difficilecolitis. Clin. Infect. Dis. 43:421–427.PubMedGoogle Scholar
  156. 156.
    Fiedenberg, F., Fernadez, A., Kaul, V., Niami, P., Levine G.M., (2001) Intravenous metro-nidazole for treatment of Clostridium difficilecolitis. Dis. Colon Rectum; 44:1176–1180.Google Scholar
  157. 157.
    Apisarnthanarak, A., Razavi, B., Mundi, L.M., (2002) Adjunctive intracolonic vancomycin for severe Clostridium difficilecolitis: case series and review of The Literative. Clin. Infect. Dis. 35:690–6961.PubMedGoogle Scholar
  158. 158.
    Shetler, K., Nieuwenhuis, R., Wren, S.M., Triadafilopoulos, G., (2001) Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseu-domembranous colitis. Surg. Endosc. 15:653–659.PubMedGoogle Scholar
  159. 159.
    Dallal, R.M., Harbrecht, B.G., Boujoukas, A.J., Sirio, C.A., Farkas, L.M., Lee, K.K., Simmons, R.L., (2003) Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Curr. Surg. 60:227–230.Google Scholar
  160. 160.
    Fekety, R., Mc Farland, L.V., Surawicz, C.M., Greenberg, R.N., Elmer, G.W., Mulligan, M. E., (1997) Recurrent Clostridium difficilediarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded clinical trial. Clin. Infect. Dis. 24:324–333.PubMedGoogle Scholar
  161. 161.
    McFarland, L.V., Surawicz, C.M., Rubin, M., Fekety, R., Elmer, G.W., Greenberg, R.N., (1999) Recurrent Clostridium difficiledisease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20:43–50.PubMedGoogle Scholar
  162. 162.
    McFarland, L.V., Elmer, G.W., Surawicz, C.M., (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficiledisease. Am. J. Gastroenterol. 97:1769–1775.PubMedGoogle Scholar
  163. 163.
    Alonso, R., Gros, S., Pelaez, T., Garcia-de-Viedma, D., Rodriguez-Creixems, M., Bouza, E., (2001) Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficileassociated diarrhea. J. Hosp. Infect. 48:86–92.PubMedGoogle Scholar
  164. 164.
    Tang-Feldman, Y., Mayo, S., Silva, J.Jr., Cohen, S.H., (2003) Molecular analysis of Clostridium difficilestrains isolated from 18 cases of recurrent Clostridium difficileassociated diarrhea. J. Clin. Microbiol. 41:3413–3414.PubMedGoogle Scholar
  165. 165.
    van den Berg, R.J., Ameen, H.A., Furusawa, T., Claas, E.C., van der Vorm, E.R., Kuijper, E. J., (2005) Coexistence of multiple PCR-ribotype strains of Clostridium difficilein faecal samples limits epidemiological studies. J. Med. Microbiol. 54:173–179.PubMedGoogle Scholar
  166. 166.
    Pepin, J., Routhier, S., Gagnon, S., Brazeau, I., (2006) Management and outcomes of a first recurrence of Clostridium difficileassociated disease in Quebec, Canada. Clin. Infect. Dis. 42:758–764.PubMedGoogle Scholar
  167. 167.
    Kyne, L., Warny, M., Qamar, A., Kelly, C.P., (2001) Association between antibody response to toxin A and protection against recurrent Clostridium difficilediarrhea. Lancet 357:158–159.Google Scholar
  168. 168.
    Kyne, L., Warny, M., Qamar, A., Kelly, C.P., (2000) Asymptomatic carriage of Clostridium difficileand serum levels of IgG antibody against toxin A.N. Engl. J. Med. 342:390–397.Google Scholar
  169. 169.
    Drudy, D., Calabi, E., Kyne, L., Sougioultzis, S., Kelly, E., Fairweather, N., Kelly, C.P., (2004) Human antibody response to surface layer proteins in Clostridium difficileinfection. FEMS Immun. Med. Microbiol. 41:237–242.Google Scholar
  170. 170.
    Dendukuri, N., Costa, V., McGregor, M., Brophy, J.M., (2005) Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 173:167–170.PubMedGoogle Scholar
  171. 171.
    Johnston, B.C., Supina, A.L., Vohra, S., (2006) Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ; 175:377–383.PubMedGoogle Scholar
  172. 172.
    McFarland, L.V., (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficiledisease. Am. J. Gastroenterol. 101:812–822.PubMedGoogle Scholar
  173. 173.
    Katz, J.A., (2006) Probiotics for the prevention of antibiotic-associated diarrhea and Clos-tridium difficilediarrhea. J. Clin. Gastroenterol. 40:249–255.PubMedGoogle Scholar
  174. 174.
    Mrukowicz, S.H., (2005) Meta-analysis: non-pathogenic yeast Saccharomyces boulardiireduces risk for antibiotic-associated diarrhea. Aliment. Pharmacol. Ther. 22:365–372.PubMedGoogle Scholar
  175. 175.
    Tedesco, F.J., Gordon, D., Forston, W.C., (1985) Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am. J. Gastroenterol. 80:867–868.PubMedGoogle Scholar
  176. 176.
    Buggy, B.P., Fekety, R., Silva, J.Jr., (1987) Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J. Clin. Gastroenterol. 9:155–159.PubMedGoogle Scholar
  177. 177.
    Leung, D.Y., Kelly, C.P., Boguniewicz, M., Pothoulakis, C., Lamont, J.T., Flores, A., (1991) Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by C. difficiletoxin. J. Pediatrics 118:633–637.Google Scholar
  178. 178.
    Salcedo, J., Keates, S., Pothoulakis, C., Warmy, M., Castagliuolo, I., Lamont, J.T., Kelly, C. P., (1997) Intravenous immunoglobulin therapy for severe Clostridium difficilecolitis. Gut 41:366–370.PubMedCrossRefGoogle Scholar
  179. 179.
    Viscidi, R., Laughon, B.E., Yolken, R., Bo-Linn, P., Moench, T., Ryder, R.W., Bartlett, J.G., (1983) Serum antibody response to toxins A and B of Clostridium difficile. J. Infect. Dis. 148:93–100.PubMedGoogle Scholar
  180. 180.
    Bacon, A.E., III, Fekety, R., (1994) Immunoglobulin G directed against toxin A and B of Clostridium difficilein the general population and patients with antibiotic-associated diarrhea. Diag. Microbiol. Infect. Dis. 18:205–209.Google Scholar
  181. 181.
    Wilcox, M.H., (2004) Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficilediarrhea. J. Antimicrob. Chemother. 53:882–884.PubMedGoogle Scholar
  182. 182.
    McPherson, S., Rees, C.J., Ellis, R., Soo, S., Panter, S.J., (2006) Intravenous immunoglobu-lin for the treatment of severe, refractory, and recurrent Clostridium difficilediarrhea. Dis. Colon Rectum 49:640–645.PubMedGoogle Scholar
  183. 183.
    Juang, P., Skledar, S.J., Zgheib, N.K., Paterson, D.L., Vergis, E.N., Shannon, W.D., Ansani, N.T., Branch, R.A., (2007) Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am. J. Infect. Control 35:131–137.PubMedGoogle Scholar
  184. 184.
    Schwan, A., Sjolin, S., Trottestam, U., Aronsson, B., (1983) Relapsing Clostridium difficileenterocolitis cured by rectal infusion of homologous faeces. Lancet 2:845PubMedGoogle Scholar
  185. 185.
    Tvede, M., Rask-Madsen, J., (1989) Bacteriotherapy for chronic relapsing Clostridiumdiarrhea in six patients. Lancet 1:1156–1160.PubMedGoogle Scholar
  186. 186.
    Persky, S.E., Brandt, L.J., (2000) Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. AM. J. Gastro-enterol. 95:3283–3285.Google Scholar
  187. 187.
    Eisenman, B., Silen, W., Bascom, G.S., Kauvar, A.J., (1958) Fecal enema as an adjunct in the treatment for pseudomembranous colitis. Surgery 44:854–859.Google Scholar
  188. 188.
    Aas, J., Gessert, C.E., Bakken, J.S., (2003) Recurrent Clostridium difficilecolitis. Case series involving 18 patients treated with donor stool administration via a nasogastric tube. Clin. Infect. Dis. 36:580–585.PubMedGoogle Scholar
  189. 189.
    Borody, T.J., Warren, E.F., Leis, S.M., Surace, R., Ashman, O., Siarakas, S., (2004) Bacteriotherapy using fecal flora: toying with human motions. J. Gastroenterol. 38:475–483.Google Scholar
  190. 190.
    Ludlam. H., Brown, N., Sule, O., Redpath, C., Coni, N., Owen, G., (1999) An antibiotic policy associated with reduced risk of Clostridium difficileassociated diarrhea. Age Ageing 28:578–580.PubMedGoogle Scholar
  191. 191.
    Carling, P., Fung, T., Killion, A., Terrin, N., Barza, M., (2003) Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect control Hosp. Epidem. 24:699–706.Google Scholar
  192. 192.
    Thomas, C., Stevenson, M., Williamson, D.J., Rily, T.V., (2002) Clostridium difficileassociated diarrhea. Epidemiological data from Western Australia associated with a modified antibiotic policy. Clin. Infect. Dis. 35:1457–1462.PubMedGoogle Scholar
  193. 193.
    Mayfield, J.L., Leet, T., Miller, J., Mundy, L.M., (2000) Environmental control to reduce transmission of Clostridium difficile. Clin. Infect. Dis. 31:995–1000.PubMedGoogle Scholar
  194. 194.
    Hopkins, M.J., Macfarlane, G.T., (2003) Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficilein vitro. Applied Environ. Microbiol, 69:1920–1927.Google Scholar
  195. 195.
    Karlsson, S., Lindberg, A., Norin, E., Burman, L.G., Akerlund, T., (2000) Toxins, butyric acid, and other shortchain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile. Infect. Immun. 68:5881–5888.PubMedGoogle Scholar
  196. 196.
    Freeman, J., Baines, S.D., Jabes, D., Wilcox, M.H., (2005) Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostriduim difficileinfection. J. Antimicrob. Chemother. 56:717–725.PubMedGoogle Scholar
  197. 197.
    Pothoulakis, C., (2004) Rifalazil treats and prevents relapse of Clostridium difficileassociated diarrhea in hamsters. Antimicrob. Agents Chemother. 48:3975–3979.PubMedGoogle Scholar
  198. 198.
    Babcock, G.J., Broering, T.J., Hernandez, H.J., Mandell, R.B., Donahue, K., Boatright, N., Stack, A.M., Lowry, I., Graziano, R., Molrine, D., Ambrosino, D.M., Thomas, W.D., (2006) Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339–6347.PubMedGoogle Scholar
  199. 199.
    Alcantra, C., Stenson, W.F., Steiner, T.S., Guerrant, R.L., (2001) Role of inducible cyclo-oxygenase and prostaglandins in Clostridium difficiletoxin A- induced secretion and inflammation in a animal model. J. Infect. Dis. 184:648–652.Google Scholar
  200. 200.
    Giannasca, P.J., Zhang, Z.X., Lei, W.D., Boden, J.A., Giel, M.A., Monath, T.P., Thomas, W. D.Jr., (1999) Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficiledisease in hamsters. Infect. Immun. 67:527–538.PubMedGoogle Scholar
  201. 201.
    Sougioultzis, S., Kyne, L., Drudy, D., Keates, S., Maroo, S., Pothoulakis, C., Giannasca, P.J., Lee, C.K., Warny, M., Monath, Kelly, T.P., Ciaran, P., (2003) Clostridium difficiletoxoid vaccine in recurrent C. difficileassociated diarrhea. Gastroenterology. 128:764–770.Google Scholar
  202. 202.
    van Dissel, J.T., de Groot, N., Hensgens, C.M., Numan, S., Kuijper, E.J., Veldkamp, P., van't Wout, J., (2005) Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficileassociated diarrhea: preclinical and preliminary clinical data. J. Med. Microbiol. 54:197–205.PubMedGoogle Scholar
  203. 203.
    Naaber, P., Lchto, E., Salminen, S., Mikelsaar, M., (1996) Inhibition of adhesion of Clostridium difficileto Ca Co-2 cells. Fems Immun. Med. Microbiol. 14:205–209.Google Scholar
  204. 204.
    Merrigan, M.M., Sambol, S.P., Johnson, S., Gerding, D.N., (2003) Prevention of fatal Clostridium difficileassociated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188:1922–1927.PubMedGoogle Scholar
  205. 205.
    Zhong, S.S., Zhang, Z.S., Wang, J.D., Lai, Z.S., Wang, Q.Y., Ren, Y.X., (2004) Competitive inhibition of adherence of enterotoxigenic Escherichia coli, enteropathogenic Escherichia coliand Clostridium difficileto intestinal epithelial cell line lovo by purified adhesin of Bifidobacterium adolescentis1027. World J. Gastroenterol. 10:1630–1633.PubMedGoogle Scholar
  206. 206.
    Fenner, L., Widmer, A.F., Goy, G., Rudin, S., Frei, R., (2008) Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J. Clin. Microbiol. 46:328–330.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Personalised recommendations